Harbor Capital Advisors Inc. boosted its position in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 4.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 49,371 shares of the company’s stock after purchasing an additional 2,076 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.06% of Kura Oncology worth $430,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of KURA. nVerses Capital LLC purchased a new stake in shares of Kura Oncology during the third quarter valued at approximately $25,000. Point72 DIFC Ltd bought a new position in Kura Oncology in the 3rd quarter valued at approximately $146,000. Quarry LP purchased a new stake in Kura Oncology during the 2nd quarter valued at $196,000. Erste Asset Management GmbH bought a new stake in shares of Kura Oncology in the 3rd quarter worth $215,000. Finally, Bellevue Group AG raised its stake in shares of Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares during the last quarter.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on the company. HC Wainwright increased their price objective on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. Jefferies Financial Group reduced their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. UBS Group started coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.38.
Kura Oncology Stock Up 0.3 %
KURA opened at $7.26 on Wednesday. The firm’s 50 day simple moving average is $11.14 and its two-hundred day simple moving average is $16.61. The company has a market capitalization of $564.57 million, a PE ratio of -3.08 and a beta of 0.81. Kura Oncology, Inc. has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Read More
- Five stocks we like better than Kura Oncology
- Conference Calls and Individual Investors
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What Are the U.K. Market Holidays? How to Invest and Trade
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Profitably Trade Stocks at 52-Week Highs
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.